

# Alexander Muir Walker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2269130/publications.pdf>

Version: 2024-02-01

58  
papers

2,002  
citations

331670

21  
h-index

233421

45  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1840  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study. <i>Jammi, 2022, 7, 14-22.</i>	0.5	1
2	Vaccine safety: looking forward and back. <i>BMJ Global Health, 2021, 6, e005743.</i>	4.7	1
3	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.</i>	3.0	6
4	Complementary hypotheses in safety surveillance. <i>Sequential Analysis, 2020, 39, 417-430.</i>	0.5	0
5	<p>Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data</p>. <i>Substance Abuse and Rehabilitation, 2019, Volume 10, 47-55.</i>	4.8	3
6	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.</i>	1.9	7
7	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety, 2018, 27, 567-569.</i>	1.9	11
8	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine, 2018, 32, 31-37.</i>	1.9	7
9	Conditional power for assessing population interventions. <i>Journal of Comparative Effectiveness Research, 2018, 7, 1027-1035.</i>	1.4	1
10	Conditional power as an aid in making interim decisions in observational studies. <i>European Journal of Epidemiology, 2018, 33, 777-784.</i>	5.7	4
11	Removal of ineligible outcome cases reduces confounding. <i>Clinical Epidemiology, 2018, Volume 10, 575-579.</i>	3.0	1
12	Tacit knowledge. <i>European Journal of Epidemiology, 2017, 32, 261-267.</i>	5.7	10
13	Possible Opioid Shopping and its Correlates. <i>Clinical Journal of Pain, 2017, 33, 976-982.</i>	1.9	11
14	For drug-induced carcinogenesis, the observations are the hypothesis. <i>Annals of Epidemiology, 2016, 26, 749-750.</i>	1.9	3
15	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. <i>Pharmacoepidemiology and Drug Safety, 2016, 25, 973-981.</i>	1.9	22
16	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.</i>	3.0	15
17	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics, 2016, 86, 62-70.</i>	3.3	30
18	Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. <i>Pharmacoepidemiology and Drug Safety, 2014, 23, 348-356.</i>	1.9	11

#	ARTICLE	IF	CITATIONS
19	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1223-1225.	1.9	4
20	Matching on provider is risky. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S65-S68.	5.0	18
21	Characterizing Vaccine-associated Risks Using Cubic Smoothing Splines. <i>American Journal of Epidemiology</i> , 2012, 176, 949-957.	3.4	2
22	Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data. <i>Epidemiology</i> , 2012, 23, 238-246.	2.7	29
23	An Eventâ€Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 631-639.	1.9	10
24	Identification of esophageal cancer in the General Practice Research Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1159-1167.	1.9	13
25	Signal detection for vaccine side effects that have not been specified in advance. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 311-317.	1.9	17
26	Orthogonal predictions: followâ€up questions for suggestive data. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 529-532.	1.9	19
27	Health care resource utilization in patients with active epilepsy. <i>Epilepsia</i> , 2010, 51, 874-882.	5.1	28
28	Active Influenza Vaccine Safety Surveillance. <i>Medical Care</i> , 2009, 47, 1251-1257.	2.4	23
29	Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 760-768.	1.9	33
30	Hospitalization for peptic ulcer and bleeding in users of selective COXâ€2 inhibitors and nonselective NSAIDs with special reference to celecoxib. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 982-988.	1.9	15
31	Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death. <i>New England Journal of Medicine</i> , 2008, 358, 771-783.	27.0	331
32	Asthma drug use and the development of Churgâ€Strauss syndrome (CSS). <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 620-626.	1.9	56
33	Coronary heart disease outcomes in patients receiving antidiabetic agents. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 711-725.	1.9	101
34	Studies of diabetes, thiazolidinediones, and coronary heart disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1313-1314.	1.9	5
35	Temporal trends and drug exposures in pulmonary hypertension: An American experience. <i>American Heart Journal</i> , 2006, 152, 521-526.	2.7	78
36	Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 47-56.	1.9	29

#	ARTICLE	IF	CITATIONS
37	Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 641-652.	1.9	41
38	Precautions for proactive surveillance. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 17-20.	1.9	6
39	Pattern recognition in health insurance claims databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 393-397.	1.9	34
40	Drug-associated antineutrophil cytoplasmic antibodyâ€“positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. <i>Arthritis and Rheumatism</i> , 2000, 43, 405.	6.7	390
41	JAMA: the Editor's dilemma. , 1999, 8, 265-266.		0
42	Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. Women. <i>Cancer</i> , 1998, 83, 2003-2007.	4.1	64
43	Prospective Study of Calcium Channel Blocker Use, Cardiovascular Disease, and Total Mortality Among Hypertensive Women. <i>Circulation</i> , 1998, 97, 1540-1548.	1.6	37
44	Prediction and Cross-Validation of Neural Networks Versus Logistic Regression: Using Hepatic Disorders as an Example. <i>American Journal of Epidemiology</i> , 1998, 147, 407-413.	3.4	39
45	Market surveillanceâ€”the complement to pharmacovigilance. , 1997, 6, 370-372.		1
46	Efficacy of a two-component acellular pertussis vaccine in infants. <i>Pediatric Infectious Disease Journal</i> , 1997, 16, 1038-1044.	2.0	97
47	Discontinuations of antihyperlipidemic drug therapy: assessment by means of automated databases. <i>Pharmacoepidemiology and Drug Safety</i> , 1996, 5, 113-120.	1.9	3
48	Common Language. , 1996, 5, 415-418.		2
49	Use of insurance claims in epidemiologic research: Identification of peptic ulcers, gi bleeding, pancreatitis, hepatitis and renal disease. <i>Pharmacoepidemiology and Drug Safety</i> , 1995, 4, 239-248.	1.9	26
50	The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 814-820.	6.7	127
51	Misclassification of covariates. <i>Statistics in Medicine</i> , 1991, 10, 1181-1196.	1.6	14
52	Uninformed criticism of automated record linkage. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 478-479.	4.7	14
53	A Comparison of Wax Matrix and Microencapsulated Potassium Chloride in Relation to Upper Gastrointestinal Illness Requiring Hospitalization. <i>Pharmacotherapy</i> , 1989, 9, 204-206.	2.6	12
54	Treatment of intrathyroidal papillary carcinoma of the thyroid. <i>Cancer</i> , 1987, 60, 2587-2595.	4.1	76

#	ARTICLE	IF	CITATIONS
55	CONJUGATED ESTROGENS AND FIBROCYSTIC BREAST DISEASE. American Journal of Epidemiology, 1986, 124, 746-751.	3.4	12
56	Age at first birth and breast atypia. International Journal of Cancer, 1984, 33, 309-312.	5.1	13
57	TEMPORAL AND REGIONAL VARIATION IN HYSTERECTOMY RATES IN THE UNITED STATES, 1970â€™1975. American Journal of Epidemiology, 1979, 110, 41-46.	3.4	37
58	The Pharmacoepidemiology of Psychiatric Medications. , 0, , 181-194.		2